12:00 AM
Feb 28, 2011
 |  BC Week In Review  |  Company News  |  Deals

MorphoSys, Novartis deal

MorphoSys received an undisclosed double-digit million Euro milestone payment from Novartis under a 2007 deal that gave Novartis preferred exclusive access to MorphoSys' HuCAL antibody technology. The payment was triggered by the installation of...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >